|
- REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key . . .
Rezpegaldesleukin is a potential first-in-class resolution therapeutic that may address this underlying immune system imbalance in people with many autoimmune and inflammatory conditions It targets the interleukin-2 receptor complex in the body to stimulate proliferation of powerful inhibitory immune cells known as regulatory T cells
- NKTR-358 | www. nektar. com
Rezpegaldesleukin (REZPEG NKTR-358) REZPEG (NKTR-358) is a novel first-in-class regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions
- The regulatory T cell-selective interleukin-2 receptor agonist . . .
Here, in two phase lb trials, the authors show that rezpegaldesleukin, a Treg-selective pegylated IL-2, is safe and improves symptoms in patients with atopic dermatitis or psoriasis
- New treatment offers fast relief for severe eczema
Rezpegaldesleukin (Rezpeg) shows fast, effective eczema relief in Phase 2 trial with fewer side effects than other treatments, offering hope for moderate-to-severe cases
- Rezpeg: A Promising New Biologic for Eczema Treatment
Rezpegaldesleukin is a new biologic drug in clinical trials for eczema Learn how it works, what makes it different, and when it might be available to patients
- Rezpegaldesleukin Potentially Promising for Atopic Dermatitis
Rezpegaldesleukin demonstrated significant efficacy in improving EASI scores and itch relief in atopic dermatitis patients, meeting primary and secondary endpoints The therapy targets the
- Rezpegaldesleukin – Application in Therapy and Current Clinical Research
Rezpegaldesleukin, also known as REZPEG or NKTR-358, is an innovative drug currently being studied in clinical trials for its potential in treating moderate to severe atopic dermatitis and severe to very severe alopecia areata
- FDA grants rezpegaldesleukin fast track to treat moderate, severe . . .
Rezpegaldesleukin (Rezpeg; Nektar Therapeutics) has been granted fast track designation by the FDA for the treatment of adult and pediatric patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescriptions, or if such therapies are not advisable 1
|
|
|